The study will evaluate the Prodisc C Vivo and Prodisc C SK devices in patients with symptomatic cervical disc disease, according to a news release. Designed to preserve motion and provide stability, total disc replacements prodisc C Vivo and prodisc C SK offer patients an alternative to cervical fusion.
DOCS aims to utilize data from the study to provide patients with the latest technology in future treatment options for musculoskeletal conditions and injuries.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
